Donate Your Heartbeats App
Apple Watch app for anonymous ECG donation to advance cardiology research
Software · Cloud SaaSCompany source
Company profile
About Idoven
Idoven has developed the world's first cardiology-as-a-service platform powered by AI that augments a clinician's ability to identify, triage and diagnose patients at scale.
Company description Idoven official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Work at Idoven?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Arrhythmias
- Atrial fibrillation
- Cardiac amyloidosis
- Cardiotoxicity
- Cardiovascular diseases
- Heart failure
- Stroke
Who it serves
- Cardiology departments
- Health systems
- Life Sciences companies
- MedTech companies
- Pharmaceutical companies
- Primary care providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: EHR systems, Electronic Health Record systems, Home Monitoring systems.
Geographic context
MarketsEurope · Global · Italy · Netherlands · Spain · Sweden · United States
Company sourceOfficial website
Company milestones
Platform expansion
AstraZeneca and Idoven launched CONCERTO project (2024-2027) to improve early diagnosis of amyloidosis. FAITHFUL Consortium launched (2024-2025) with €1.7 million from EIT Health Spain involving 14 international institutions. Featured on cover of Forward: Unlocking Europe's AI Potential (September 2025).
Partnerships
Recorded partners
- AstraZeneca
- EIT Health Spain
- Google for Startups Campus
- Iker Casillas Foundation
- MAESTRIA H2020 Consortium
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Life Sciences Solution
ECG-based digital biomarkers for disease prediction and cardiotoxicity monitoring
Platform · Cloud SaaSCompany source
MedTech Solution
Digital diagnostics and cloud-based ECG interpretation for medical device companies
Platform · Cloud SaaSCompany source
Preventative Screening Programs
Remote ECG monitoring and digital screening for employee health programs
Service · Cloud SaaSCompany source
Willem
AI-powered ECG analysis platform for cardiology-as-a-service
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Improving transthyretin cardiac amyloidosis detection from electrocardiograms through the Willem artificial intelligence platform.Heart rhythm · Jul 1, 2026
Enhanced detection of atrial fibrillation in single-lead electrocardiograms using a Cloud-based artificial intelligence platform.Heart rhythm · Jul 1, 2025
Rationale and design of the artificial intelligence scalable solution for acute myocardial infarction (ASSIST) study.Journal of electrocardiology · Jan 1, 2024
Current and Future Use of Artificial Intelligence in Electrocardiography.Journal of cardiovascular development and disease · Apr 17, 2023
Artificial intelligence cloud platform improves arrhythmia detection from insertable cardiac monitors to 25 cardiac rhythm patterns through multi-label classification.Journal of electrocardiology · Jan 1, 2023
Artificial intelligence augments detection accuracy of cardiac insertable cardiac monitors: Results from a pilot prospective observational study.Cardiovascular digital health journal · Oct 1, 2022
Clinical validation
Clinical-trial records
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)NCT05890716 · Sponsor · RECRUITING
Artificial Intelligence Scalable Solution for ST Myocardial InfarctionNCT06939738 · Sponsor · COMPLETED
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis DiagnosisNCT06978660 · Sponsor · RECRUITING
Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)NCT07113223 · Sponsor · RECRUITING
Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG PlatformNCT07333547 · Sponsor · RECRUITING
Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram StudyNCT07479992 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
40% reduction in hospitalizations
FAITHFUL Consortium heart failure detection in primary care
Cardiologist-level accuracy
Detection of 22 cardiac patterns
Minutes
Time to deliver ECG analysis results
AstraZeneca
CONCERTO project to improve early diagnosis of patients with cardiac amyloidosis using AI-powered ECG analysis
Partnership launched to detect subtle patterns signaling early signs of amyloidosis that are often missed by experienced cardiologists, addressing diagnostic delays of up to 4 years
FAITHFUL Consortium
Augmenting heart failure detection in primary care with AI ECG platform across 14 leading international institutions
Anticipated 40% reduction in hospitalizations leading to significant healthcare cost savings, backed by €1.7 million from EIT Health Spain
Iker Casillas Foundation
Personal cardiac monitoring and cardiovascular disease prevention research for vulnerable groups at high risk
Partnership established to impact lives of vulnerable groups at high risk of cardiovascular diseases through the #donateyourheartbeats movement
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Idoven
Recent articles published on Idoven's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.